Navigation Links
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Date:3/11/2009

New use for PEGINTRON(TM) and REBETOL(R) offers certain patients a second chance to achieve treatment success

KENILWORTH, N.J., March 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved new labeling for PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for treating chronic hepatitis C in patients 3 years of age and older with compensated liver disease. With approval of this expanded indication, PEGINTRON and REBETOL is the first and only pegylated interferon combination therapy approved in the United States that is not restricted to treatment-naive patients. Patients less likely to benefit from retreatment after failing a course of therapy include those with previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, or HCV genotype 1 infection. It is estimated that more than 100,000 patients in the United States failed prior treatment of their hepatitis C virus (HCV) infection, representing a large and growing patient population.

"With the FDA approval of PEGINTRON and REBETOL combination therapy for this new indication, U.S. physicians now have a treatment option that offers a second chance for success to certain patients who failed prior therapy," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "This approval further underscores Schering-Plough's leadership and long-term commitment to developing new treatment options and innovative therapies to meet the needs of patients with hepatitis C."

Data from the clinical study supporting the approval helped to define those patient groups most likely to respond to retreatment as well as those unlikely to respond. Overall, p
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of ... Board of Directors has authorized the implementation of a 1:25 ... be completed on or before January 15, 2012. ... by the Company,s stockholders at a November 4, 2011, special ...
... EXTON, Pa., Jan. 3, 2012 ViroPharma Incorporated (Nasdaq: ... Julie H. McHugh to its board of directors. ... health care industry experience and leadership to ViroPharma,s Board ... of Endo Pharmaceuticals, a U.S.-based, specialty healthcare solutions company.  ...
Cached Medicine Technology:Radient Pharmaceuticals Announces Reverse Stock Split 2ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors 2
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... , ... LLP (ENTA) announced today that it has expanded the implementation of its state-of-the-art Electronic Medical ... City, Long Island, Westchester, Rockland, Putnam and Orange Counties and northern New Jersey. All of ... ...
... ... Department of Corrections , ... Miami, FL (PRWEB) July 1, 2010 -- JPay.com, the Trusted Leader in ... million offenders nationwide with absolutely no cost to correctional departments and today announced the ...
... ... the release of their new Alpha 3C™ formula, designed to naturally support focus, ... ... provider of premium dietary supplements, announces the release of their new Alpha 3C™ ...
... that older adults commonly have low vitamin D levels and ... the metabolic syndrome, a condition that affects one in four ... Annual Meeting in San Diego. "Because the metabolic syndrome ... vitamin D level in the body might be important in ...
... men with higher testosterone levels are more likely to ... the future. The results were presented at The Endocrine ... study finding contradicts smaller studies that have shown that ... cardiovascular disease," said presenting author Kristen Sueoka, MD, a ...
... ... Marijuana emerges as the most popular plant in the United States we,re still ... Casias is a perfect example of the discrimination as at the young age ... been forced to fight Wal-Mart after losing his job for using medicinal marijuana ...
Cached Medicine News:Health News:ENT and Allergy Associates, LLP Expands its New Electronic Practice Management System (EMR) 2Health News:ENT and Allergy Associates, LLP Expands its New Electronic Practice Management System (EMR) 3Health News:JPay, the Apple of Washington State DOC's eye 2Health News:Purity Products Releases Alpha 3C 2Health News:Low vitamin D linked to the metabolic syndrome in elderly people 2Health News:Higher testosterone may raise risk of heart disease in elderly men 2Health News:Fired Wal-Mart Employee Accepts Full Scholarship to The Medical Marijuana Academy 2
... O.R. Special Protective Apron is made ... and a sterile gown. Uniquely it ... sterile field. Reaching through the back ... are released, and the protective apron ...
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
... coat apron, weight is distributed uniformly ... comfortable wear without fatigue. Made to ... front closing special procedure apron comes ... that make it a cinch to ...
... Wolfs Easy Wrap Apron has always ... easy to put-on, adjust and take-off. Our ... new Easy sures Wrap features two velcro ... The attached Thyroid collar adjusted to fully ...
Medicine Products: